MA38100A1 - Forme solide d'un dérivé de dihydro-pyrido-oxazine - Google Patents

Forme solide d'un dérivé de dihydro-pyrido-oxazine

Info

Publication number
MA38100A1
MA38100A1 MA38100A MA38100A MA38100A1 MA 38100 A1 MA38100 A1 MA 38100A1 MA 38100 A MA38100 A MA 38100A MA 38100 A MA38100 A MA 38100A MA 38100 A1 MA38100 A1 MA 38100A1
Authority
MA
Morocco
Prior art keywords
dihydro
pyridooxazine
derivative
solid form
forms
Prior art date
Application number
MA38100A
Other languages
English (en)
Inventor
Konstanze Hurth
Christoph Kalis
Karen Kammertoens
Nicolas Soldermann
Frederic Zecri
Original Assignee
Novartis Ag
Konstanze Hurth
Christoph Kalis
Karen Kammertoens
Nicolas Soldermann
Frederic Zecri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Konstanze Hurth, Christoph Kalis, Karen Kammertoens, Nicolas Soldermann, Frederic Zecri filed Critical Novartis Ag
Priority claimed from PCT/IB2013/060412 external-priority patent/WO2014102630A1/fr
Publication of MA38100A1 publication Critical patent/MA38100A1/fr

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne une forme cristalline anhydre de (1,1-dioxo-hexahydro-1lambda*6*- thiopyran-4-yl)-{(s)-3-[1-(6-méthoxy-5-méthyl-pyridin-3-yl)-2,3-dihydro-1h-pyrido[3,4-b][1,4]oxazin-7-yloxy]-pyrrolidin-1-yl}-méthanone; des compositions et des combinaisons pharmaceutiques incluant ces formes ainsi que des procédés d'utilisation de ces formes, incluant leurs compositions et combinaisons pharmaceutiques pour le traitement de maladies.
MA38100A 2012-11-26 2013-11-26 Forme solide d'un dérivé de dihydro-pyrido-oxazine MA38100A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GC201222895 2012-11-26
PCT/IB2013/060412 WO2014102630A1 (fr) 2012-11-26 2013-11-26 Forme solide d'un dérivé de dihydro-pyrido-oxazine

Publications (1)

Publication Number Publication Date
MA38100A1 true MA38100A1 (fr) 2017-12-29

Family

ID=54198861

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38100A MA38100A1 (fr) 2012-11-26 2013-11-26 Forme solide d'un dérivé de dihydro-pyrido-oxazine

Country Status (8)

Country Link
JP (1) JP6310474B2 (fr)
EA (1) EA028031B1 (fr)
ES (1) ES2643902T3 (fr)
HR (1) HRP20171573T1 (fr)
HU (1) HUE036665T2 (fr)
LT (1) LT2928896T (fr)
MA (1) MA38100A1 (fr)
SI (1) SI2928896T1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
MY170922A (en) * 2011-12-22 2019-09-18 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives

Also Published As

Publication number Publication date
HUE036665T2 (hu) 2018-07-30
LT2928896T (lt) 2017-09-25
JP2016502531A (ja) 2016-01-28
HRP20171573T1 (hr) 2017-11-17
EA028031B1 (ru) 2017-09-29
JP6310474B2 (ja) 2018-04-11
EA201591023A1 (ru) 2015-09-30
SI2928896T1 (sl) 2017-10-30
ES2643902T3 (es) 2017-11-27

Similar Documents

Publication Publication Date Title
MA31470B1 (fr) Dérivés de pipéridine utiles comme antagonistes vis-à-vis des récepteurs de l'orexine
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA37379A1 (fr) Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
MY150518A (en) Substituted gamma lactams as therapeutic agents
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
MA33132B1 (fr) Derives pyrazole utilises comme antagonistes du recepteur ccr4
MA34641B1 (fr) Anticorps anti-il-23
IL193479A0 (en) Modulators of muscarinic receptors
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
EA201070912A1 (ru) Производные оксима в качестве ингибиторов hsp90
EP2614860A4 (fr) Composition pharmaceutique pour le traitement de l'oeil sec
MA38071A1 (fr) Formes cristallines d'un inhibiteur de facteur xia
MA38714A1 (fr) Procédés de production et formes cristallines d'un inhibiteur mdm2
ECSP099621A (es) Derivados de ciclohexano espirociclico
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
GEP20135806B (en) Lactams as beta secretase inhibitors
EP2328417A4 (fr) COMPOSÉS, COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE MALADIES DE LA béta-AMYLOÏDE ET DE SYNUCLÉINOPATHIES
PH12013501321A1 (en) Phenoxymethyl heterocyclic compounds
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EA201170997A1 (ru) Производные индола в качестве противораковых агентов
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
MA39163A1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine